A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery disease (CAD) and a blood pressure in the pre-hypertensive range.
Inclusion Criteria:
Exclusion Criteria:
Baseline IVUS determined unacceptable
Patients requiring treatment with disallowed study medications
Patients with clinically significant heart disease
Previous or current diagnosis of heart failure (NYHA Class IV) or a documented left ventricular ejection fraction of < 25%
Patients requiring treatment with any 2 of the following classes of medication at Visit 1 or Visit 2:
Other conditions may apply
Buenos Aires, Buenos Aires C1039AAP, Argentina
Buenos Aires, Buenos Aires C1210AAP, Argentina
Buenos Aires, Buenos Aires C1280AEB, Argentina
Buenos Aires, Buenos Aires C1426ANZ, Argentina
Buenos Aires, Buenos Aires C1428DCO, Argentina
Lódz, 90-549, Poland
Galdakano, Basque Country 48960, Spain
Majadanonda, Madrid 28220, Spain